TSXV:SQD.H - Post by User
Post by
xqxon Aug 08, 2014 4:58am
198 Views
Post# 22821052
Excerpts from the current MD&A
Excerpts from the current MD&A "The Company is currently in the process of finalizing a commercial contract with Isis’s CRO to implement the SQI-developed test in clinical testing, which could result in material revenues to the Company in fiscal 2014 with the CRO’s validation work expected to start in August, 2014"
"We anticipate that many of the successful evaluation projects completed over the last nine months will proceed to the next expected commercial phases, where SQI will produce and sell test kits to these customers for either its fully automated sqidlite or semi-automated sqid-X platforms. Within each Pharma customer, we are also seeking opportunities to expand the scope of ongoing programs and to develop new product opportunities."
"Management expects to reduce losses later in fiscal 2014 as it generates revenues and margin from a variety of Diagnostic Tools and Services’ customers. Successful US FDA clearance of its IVD Celiac test could result in initial revenue from that product in late fiscal 2014, further reducing overall losses."